A complete application in a minute
Tailored resume and cover letter, ready to send.
Monte Rosa Therapeutics is seeking a Senior Manager / Associate Director, Regulatory Strategy - CMC to lead regulatory strategy across oncology, immunology, and related areas from Basel. You will manage IND/CTA filings, interact with FDA/EMA, and ensure global compliance while partnering with internal and external stakeholders.
The role requires 5+ years in global regulatory affairs, strong program management, and the ability to drive submissions and strategy across cross-functional teams in a
Senior Manager / Associate Director, Regulatory Strategy - CMC
Location: Basel
Monte Rosa Therapeutics is seeking a highly skilled and self-motivated regulatory professional to join our teams. This role will focus on oncology, immunology, and related therapeutic areas. The successful candidate will be responsible for developing and implementing regulatory strategies to support the global development and approval of our innovative therapies.
Monte Rosa Therapeutics (MRT) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.
To learn more about MRTx, visit www.monterosatx.com